U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula Zn
Molecular Weight 65.3956
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 2

SHOW SMILES / InChI
Structure of ZINC CATION

SMILES

[ZnH2+2]

InChI

InChIKey=PTFCDOFLOPIGGS-UHFFFAOYSA-N
InChI=1S/Zn/q+2

HIDE SMILES / InChI

Molecular Formula Zn
Molecular Weight 65.3956
Charge 2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

CNS Activity

Curator's Comment:: Spatial memory deficits in a mouse model of late-onset Alzheimer's disease were caused by Zinc Carbonate supplementation. Long-term dietary administration of zinc ( Zinc Carbonate) can lead to impairments in cognitive function in rats. Microprobe synchrotron X-ray fluorescence (microSXRF) confirmed that brain zinc levels were increased by adding Zinc Carbonate to the drinking water.

Originator

Curator's Comment:: Centuries before zinc was recognized as a distinct element, zinc ores were used for making brass (a mixture of copper and zinc). A brass dating from between 1400-1000 BC has been found in Palestine. An alloy containing 87% zinc was found in prehistoric ruins in Transylvania. The smelting of zinc ores with copper was apparently discovered in Cyprus and was used later by the Romans. Metallic zinc was produced in the 13th century in India by reducing calamine (zinc carbonate, ZnCO3) with organic substances such as wool. The metal was rediscovered later in Europe. William Champion set up a zinc industry in Bristol (England) in the 1740s.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: ultraviolet B-induced damage
Target ID: Q9NY26
Gene ID: 27173.0
Gene Symbol: SLC39A1
Target Organism: Homo sapiens (Human)
Target ID: Q9NP94
Gene ID: 29986.0
Gene Symbol: SLC39A2
Target Organism: Homo sapiens (Human)
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
Unknown

Approved Use

Unknown
Primary
CORTROPHIN-ZINC

Approved Use

Treatment of ulcerative colitis and other colonic disorders.

Launch Date

-4.55328006E11
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Secondary
VORAXAZE

Approved Use

Indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function. Limitation of use: VORAXAZE is not indicated for use in patients who exhibit the expected clearance of methotrexate (plasma methotrexate concentrations within 2 standard deviations of the mean methotrexate excretion curve specific for the dose of methotrexate administered) or those with normal or mildly impaired renal function because of the potential risk of subtherapeutic exposure to methotrexate.

Launch Date

1.32675836E12
Primary
VUSION

Approved Use

INDICATIONS AND USAGE VUSION Ointment is indicated for the adjunctive treatment of diaper dermatitis only when complicated by documented candidiasis (microscopic evidence of pseudohyphae and/or budding yeast), in immunocompetent pediatric patients 4 weeks and older. A positive fungal culture for Candida albicans is not adequate evidence of candidal infection since colonization with C. albicans can result in a positive culture. The presence of candidal infection should be established by microscopic evaluation prior to initiating treatment. VUSION Ointment should be used as part of a treatment regimen that includes measures directed at the underlying diaper dermatitis, including gentle cleansing of the diaper area and frequent diaper changes.

Launch Date

1.140048E12
Primary
ZINC OXIDE

Approved Use

Unknown
Primary
ZINC SULFATE

Approved Use

Unknown

Launch Date

5.47171205E11
Primary
ZINC SULFATE

Approved Use

Unknown

Launch Date

5.47171205E11
Primary
ZINC SULFATE

Approved Use

Unknown

Launch Date

5.47171205E11
PubMed

PubMed

TitleDatePubMed
In vitro activity of zinc salts against human rhinoviruses.
1987 Apr
Zinc inhibition of renin and the protease from human immunodeficiency virus type 1.
1991 Sep 10
Molecular modeling studies suggest that zinc ions inhibit HIV-1 protease by binding at catalytic aspartates.
1993 Aug
New applications for the zinc iodide-osmium tetroxide technique.
1994 Feb
Iron chelators as therapeutic agents against Pneumocystis carinii.
1994 May
Cupric ion blocks NF kappa B activation through inhibiting the signal-induced phosphorylation of I kappa B alpha.
1995 Nov 13
SRR-SB3, a disulfide-containing macrolide that inhibits a late stage of the replicative cycle of human immunodeficiency virus.
1997 Feb
Enantioselective Cyclopropanation of Allylic Alcohols. The Effect of Zinc Iodide.
1997 May 16
Thujaplicin-copper chelates inhibit replication of human influenza viruses.
1998 Aug
Combined effects of argon laser irradiation and fluoride treatments in prevention of caries-like lesion formation in enamel: an in vitro study.
1999 Spring
Comparison of the levels of copper, zinc and iron in cervical mucus and in blood serum of women of childbearing age.
2004
Impact of the mother's zinc deficiency on the woman's and newborn's health status.
2005
Zinc in attention-deficit/hyperactivity disorder.
2005 Aug
Angiotensin II receptor blocker-induces blunted taste sensitivity: comparison of candesartan and valsartan.
2005 Aug
Copper, zinc, and Cu/Zn ratio in carcinoma of the gallbladder.
2005 Sep 1
Effects of zinc supplementation in patients with type 1 diabetes.
2005 Summer
Copper and zinc concentrations in serum of healthy Greek adults.
2006 Apr 15
Effect of end-stage renal disease and diabetes on zinc and copper status.
2006 Jul
Elevated cortical zinc in Alzheimer disease.
2006 Jul 11
Seminal plasma zinc concentration and alpha-glucosidase activity with respect to semen quality.
2006 May
Marginal zinc deficiency increased the susceptibility to acute lipopolysaccharide-induced liver injury in rats.
2006 May
On the mechanism of the conversion of methanol to 2,2,3-trimethylbutane (triptane) over zinc iodide.
2006 Nov 10
Assessing toxicity of fine and nanoparticles: comparing in vitro measurements to in vivo pulmonary toxicity profiles.
2007 May
Glucarpidase (carboxypeptidase g2) intervention in adult and elderly cancer patients with renal dysfunction and delayed methotrexate elimination after high-dose methotrexate therapy.
2007 Nov
Difficulty measuring methotrexate in a patient with high-dose methotrexate-induced nephrotoxicity.
2010 Dec
Metal oxide nanoparticles induce unique inflammatory footprints in the lung: important implications for nanoparticle testing.
2010 Dec
In vivo uptake and acute immune response to orally administered chitosan and PEG coated PLGA nanoparticles.
2010 Dec 1
Oxidative stress, calcium homeostasis, and altered gene expression in human lung epithelial cells exposed to ZnO nanoparticles.
2010 Feb
Glucarpidase following high-dose methotrexate: update on development.
2010 Jan
Phosphorylation of p65 is required for zinc oxide nanoparticle-induced interleukin 8 expression in human bronchial epithelial cells.
2010 Jul
Quantum dots trigger immunomodulation of the NFκB pathway in human skin cells.
2011 Jul
Glucarpidase rescue in a patient with high-dose methotrexate-induced nephrotoxicity.
2011 Jun
High-dose methotrexate-induced renal dysfunction: is glucarpidase necessary for rescue?
2011 Mar 1
Responses of human cells to ZnO nanoparticles: a gene transcription study.
2011 Nov
Zeta potential and solubility to toxic ions as mechanisms of lung inflammation caused by metal/metal oxide nanoparticles.
2012 Apr
Aerosolized ZnO nanoparticles induce toxicity in alveolar type II epithelial cells at the air-liquid interface.
2012 Feb
Association of zinc ion release and oxidative stress induced by intratracheal instillation of ZnO nanoparticles to rat lung.
2012 Jun 25
Standard molar enthalpy of combustion and formation of quaternary ammonium tetrachlorozincate [n-CnH2n+1 N(CH3)3]2 ZnCl4.
2013 Dec
Zinc oxide nanoparticles inhibit Ca2+-ATPase expression in human lens epithelial cells under UVB irradiation.
2013 Dec
Sensitivity of human dental pulp cells to eighteen chemical agents used for endodontic treatments in dentistry.
2013 Jan
TiO2, CeO2 and ZnO nanoparticles and modulation of the degranulation process in human neutrophils.
2013 Jul 31
Cytotoxicity in the age of nano: the role of fourth period transition metal oxide nanoparticle physicochemical properties.
2013 Nov 25
Involvement of MyD88 in zinc oxide nanoparticle-induced lung inflammation.
2013 Sep
Mechanism of uptake of ZnO nanoparticles and inflammatory responses in macrophages require PI3K mediated MAPKs signaling.
2014 Apr
Nanosized zinc oxide particles do not promote DHPN-induced lung carcinogenesis but cause reversible epithelial hyperplasia of terminal bronchioles.
2014 Jan
Zinc oxide nanoparticles induce migration and adhesion of monocytes to endothelial cells and accelerate foam cell formation.
2014 Jul 1
Glucarpidase for the management of elevated methotrexate levels in patients with impaired renal function.
2014 May 15
Immunomodulatory activity of zinc peroxide (ZnO₂) and titanium dioxide (TiO₂) nanoparticles and their effects on DNA and protein integrity.
2014 May 16
Synthesis aspects, structural, spectroscopic, antimicrobial and room temperature ferromagnetism of zinc iodide complex with Schiff based ligand.
2015 Jan 25
Practical considerations for the administration of glucarpidase in high-dose methotrexate (HDMTX) induced renal dysfunction.
2015 Sep
Patents

Sample Use Guides

In Vivo Use Guide
Unknown
Route of Administration: Unknown
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Fri Jun 25 21:26:35 UTC 2021
Edited
by admin
on Fri Jun 25 21:26:35 UTC 2021
Record UNII
13S1S8SF37
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ZINC CATION
Common Name English
ZINC ION
Common Name English
ZINC(II)
Systematic Name English
ZINC ION(2+)
Common Name English
ZINC(2+)
Systematic Name English
ZINC, ION (ZN2+)
Common Name English
Classification Tree Code System Code
NDF-RT N0000175530
Created by admin on Fri Jun 25 21:26:36 UTC 2021 , Edited by admin on Fri Jun 25 21:26:36 UTC 2021
WHO-ATC D09AB01
Created by admin on Fri Jun 25 21:26:36 UTC 2021 , Edited by admin on Fri Jun 25 21:26:36 UTC 2021
NCI_THESAURUS C68295
Created by admin on Fri Jun 25 21:26:36 UTC 2021 , Edited by admin on Fri Jun 25 21:26:36 UTC 2021
NCI_THESAURUS C597
Created by admin on Fri Jun 25 21:26:36 UTC 2021 , Edited by admin on Fri Jun 25 21:26:36 UTC 2021
DSLD 137 (Number of products:9660)
Created by admin on Fri Jun 25 21:26:36 UTC 2021 , Edited by admin on Fri Jun 25 21:26:36 UTC 2021
Code System Code Type Description
FDA UNII
13S1S8SF37
Created by admin on Fri Jun 25 21:26:36 UTC 2021 , Edited by admin on Fri Jun 25 21:26:36 UTC 2021
PRIMARY
DRUG BANK
DB14532
Created by admin on Fri Jun 25 21:26:36 UTC 2021 , Edited by admin on Fri Jun 25 21:26:36 UTC 2021
PRIMARY
NDF-RT
N0000175529
Created by admin on Fri Jun 25 21:26:36 UTC 2021 , Edited by admin on Fri Jun 25 21:26:36 UTC 2021
PRIMARY Decreased Copper Ion Absorption [PE]
PUBCHEM
32051
Created by admin on Fri Jun 25 21:26:36 UTC 2021 , Edited by admin on Fri Jun 25 21:26:36 UTC 2021
PRIMARY
RXCUI
1546264
Created by admin on Fri Jun 25 21:26:36 UTC 2021 , Edited by admin on Fri Jun 25 21:26:36 UTC 2021
PRIMARY RxNorm
NCI_THESAURUS
C68296
Created by admin on Fri Jun 25 21:26:36 UTC 2021 , Edited by admin on Fri Jun 25 21:26:36 UTC 2021
PRIMARY
CAS
23713-49-7
Created by admin on Fri Jun 25 21:26:35 UTC 2021 , Edited by admin on Fri Jun 25 21:26:35 UTC 2021
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
LIGAND->TARGET
Scientific Literature
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY